# AMD 3100 for Treatment of Myelokathexis

> **NCT01058993** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 6 (actual)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** AMD3100 or plerixafor

## Key facts

- **NCT ID:** NCT01058993
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2012-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058993, "AMD 3100 for Treatment of Myelokathexis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01058993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*